Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial
Abdulazeez Salawu, Ben X Wang, Ming Han, et al.
Clinical Colorectal Cancer
|
July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
Alberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
Ignacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
JCO Precision Oncology
|
August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Elena Garralda, Charles Abbott, Alma Calahorro, et al.
The Lancet Regional Health. Europe
|
November 12, 2024
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study
Oriol Mirallas, Berta Martin-Cullell, Víctor Navarro, et al.
Nature
|
February 25, 2025
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Nature
|
December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial
Abdulazeez Salawu, Ben X Wang, Ming Han, et al.
Clinical Colorectal Cancer
|
July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
Alberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
Ignacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
JCO Precision Oncology
|
August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Elena Garralda, Charles Abbott, Alma Calahorro, et al.
The Lancet Regional Health. Europe
|
November 12, 2024
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study
Oriol Mirallas, Berta Martin-Cullell, Víctor Navarro, et al.
Nature
|
February 25, 2025
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Nature
|
December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Page
of 4